# Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT01371981** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 1645 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Leukemia Cutis
- Myeloid Neoplasm
- Myeloid Sarcoma

## Interventions

- **DRUG:** Asparaginase
- **DRUG:** Bortezomib
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mitoxantrone Hydrochloride
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT01371981
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06-20
- **Primary completion:** 2019-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 1645 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371981, "Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01371981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*